Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.38 |
| ▸ | RXRA | P19793 | 14/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24380230 | 0.90 | IMPDH2 (0.39) | NR1H2RXRANR1H3 | |
| SCHEMBL29616596 | 0.86 | NR1H2 (0.39) | NR1H2RXRANR1H3 | |
| SCHEMBL30917881 | 0.86 | NR1H2 (0.39) | NR1H2RXRANR1H3 | |
| SCHEMBL31036479 | 0.86 | NR1H2 (0.39) | NR1H2RXRANR1H3 | |
| SCHEMBL27034795 | 0.86 | NR1H2 (0.39) | NR1H2RXRANR1H3 | |
| SCHEMBL24451644 | 0.86 | IP6K1 (0.40) | NR1H2RXRANR1H3 | |
| SCHEMBL24454023 | 0.86 | IP6K1 (0.40) | NR1H2RXRANR1H3 | |
| SCHEMBL24380260 | 0.85 | NR1H2 (0.35) | NR1H2RXRANR1H3 | |
| SCHEMBL24403239 | 0.83 | NR1H2 (0.48) | NR1H2RXRANR1H3 | |
| SCHEMBL24403238 | 0.83 | NR1H2 (0.48) | NR1H2RXRANR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023009187-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023003610-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | NR1H2 633/4885RXRA 4729/4885NR1H3 538/4885 |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | NR1H2 555/4885RXRA 4645/4885NR1H3 470/4885 |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | NR1H2 429/4885RXRA 4740/4885NR1H3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.